genOway has been signed up to provide the Beth Israel Deaconess Medical Center (BIDMC) with genetically modified rodents for its medical research. The deal takes the form of a two-year, renewable-framework agreement.


genOway is a service provider dedicated to the development of genetically modified mouse and rat models. The company’s technologies include its Safe DNA Transgenesis™, Safe RNAi Transgenesis™, Safe in vivo RNAi™, and Quick Knock-in™ platforms.

Previous articleAmbry Partners with SoftGenetics to Provide Extended Bioinformatics Services for Next-Gen Sequencing
Next articleNovo Nordisk Pays ZymoGenetics $24M Up Front for Expanded Rights to IL-21 mAb Technology